Studies on the affinity of 6-[(n-(cyclo)aminoalkyl)oxy]-4H-chromen-4-ones for sigma 1/2 receptors

Sigma (σ) receptors represent attractive targets for the development of potential agents for the treatment of several disorders, including Alzheimer's disease and neuropathic pain. In the search for multitarget small molecules (MSMs) against such disorders, we have re-discovered chromenones as...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2021-06, Vol.12 (6), p.1000-1004
Main Authors: Deuther-Conrad, Winnie, Diez-Iriepa, Daniel, Iriepa, Isabel, López-Muñoz, Francisco, María Angeles Martínez-Grau, Gütschow, Michael, Marco-Contelles, José
Format: Article
Language:English
Subjects:
Acetylcholinesterase
Affinity
Alzheimer's disease
Amine oxidase (flavin-containing)
Chemistry
Cytotoxicity
Disorders
Neuralgia
Neurodegenerative diseases
Pain
Receptors
Selectivity
Toxicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sigma (σ) receptors represent attractive targets for the development of potential agents for the treatment of several disorders, including Alzheimer's disease and neuropathic pain. In the search for multitarget small molecules (MSMs) against such disorders, we have re-discovered chromenones as new affine σ1/σ2 ligands. 6-(4-(Piperidin-1-yl)butoxy)-4H-chromen-4-one (7), a previously identified MSM with potent dual-target activities against acetylcholinesterase and monoamine oxidase B, also exhibited σ1/σ2 affinity. 6-(3-(Azepan-1-yl)propoxy)-4H-chromen-4-one (20) showed a Ki value for σ1 of 27.2 nM (selectivity (σ1/σ2) = 28), combining the desired σ1 receptor affinity with a dual inhibitory capacity against both acetyl- and butyrylcholinesterase. 6-((5-Morpholinopentyl)oxy)-4H-chromen-4-one (12) was almost equipotent to S1RA, an established σ1 receptor antagonist.
ISSN:2040-2503
2040-2511
2632-8682
DOI:10.1039/d1md00105a